Emergent Revises Upward 2010 Financial Forecast
Company anticipates total revenues of $275 to $300 million and net income of $40 to $50 million
ROCKVILLE, MD, July 20, 2010 – Emergent BioSolutions Inc. (NYSE:EBS) announced today that it is revising upwards its 2010 annual guidance to now reflect anticipated total revenues of $275 to $300 million and net income of [...]
In: Biothrax, Chief Executive Officer, Emergent Bioslutions, Food and Drug Administration, Fuad El-Hibri, Shareholder · Tagged with: Anthrax vaccines, Biothrax, Emergent BioSolutions, Food and Drug Administration, Infectious disease, Strategic National Stockpile, United States, US government
Emergent BioSolutions Awarded HHS Contract Valued at Up to $107 Million to Develop Large-Scale Manufacturing for BioThrax
ROCKVILLE, Md., Jul 14, 2010
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has signed a contract valued at up to $107 million with the Office of the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services (HHS), to develop and obtain regulatory approval for large-scale [...]
In: Business, Chief Executive Officer, Emergent Bioslutions, Food and Drug Administration · Tagged with: Anthrax vaccines, Biothrax, Emergent BioSolutions, Food and Drug Administration, Infectious disease, US government
EMERGENT BIOSOLUTIONS ANTICIPATES 2ND QUARTER BIOTHRAX REVENUES OF APPROXIMATELY $20 MILLION BASED ON ACCELERATED DELIVERY TO DEPARTMENT OF DEFENSE
ROCKVILLE, MD, June 27, 2007—Emergent BioSolutions Inc. (NYSE: EBS), a biopharmaceutical company, announced today that, pursuant to the terms of an amended contract with the U.S. Department of Defense (DoD), it anticipates completing delivery of 900,000 doses of BioThrax® (Anthrax Vaccine Adsorbed) during the quarter ending June 30, 2007 or shortly thereafter. The company anticipates [...]
In: Uncategorized · Tagged with: Anthrax vaccines, Emergent BioSolutions, Infectious disease, Private Securities Litigation Reform Act, U.S. Department of Defense, United States, US Food and Drug Administration, US government
EMERGENT BIOSOLUTIONS ANNOUNCES EXPANSION OF BOARD OF DIRECTORS AND APPOINTMENT OF DR. SUE BAILEY TO THE COMPANY’S BOARD OF DIRECTORS
ROCKVILLE, MD, June 15, 2007—Emergent BioSolutions Inc. (NYSE: EBS), a biopharmaceutical company, announced today that at a regularly scheduled meeting of its board of directors the board passed a resolution authorizing the expansion of the total number of members of the board to eight. The board also unanimously appointed Sue Bailey, M.D., as a Class [...]
In: Uncategorized · Tagged with: Federal government of the United States, Johns Hopkins University, Medicine, United States, United States armed forces, United States Secretary of Defense, US Food and Drug Administration, US government
Emergent BioSolutions Anticipates 2nd Quarter BioThrax Revenues of Approximately $20 Million Based on Accelerated Delivery to Department of Defense.
Company Preparing Response to DoD Request for Proposal for Delivery of Up to 14 Million Additional Doses of BioThrax
ROCKVILLE, Md. — Emergent BioSolutions Inc. (NYSE:EBS), a biopharmaceutical company, announced today that, pursuant to the terms of an amended contract with the U.S. Departmentof Defense (DoD), it anticipates completing delivery of 900,000 doses of BioThrax([R]) (Anthrax [...]
In: Uncategorized · Tagged with: Anthrax vaccines, Chief executive officer, Emergent BioSolutions, Federal government of the United States, Immunization, United States, United States Department of Defense, US government
Emergent Biosolutions Submits Proposal In Response To Hhs’ Rfp For Development And Procurement Of A Recombinant Protective Antigen Anthrax Vaccine
The company’s submission provides the U.S. Government with the critical option to select a domestic source to meet planned procurement of 25 million doses of rPA vaccine.
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has submitted a proposal in response to a request for proposal (RFP) issued by the U.S. Department of Health and [...]
In: Uncategorized · Tagged with: Clinical trial, Infectious disease, rPA 102, Strategic National Stockpile, United States, United States Department of Health and Human Services, US Food and Drug Administration, US government
Emergent Biosolutions Acquires Advanced Recombinant Protective Antigen Anthrax Vaccine Candidate And Technology
Acquisition positions Emergent to offer the U.S. Government a domestic source for an advanced anthrax vaccine candidate to meet planned procurement of 25 million doses of rPA vaccine.
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has completed the acquisition of all assets and rights related to a recombinant protective antigen (rPA) anthrax vaccine product [...]
In: Uncategorized · Tagged with: Clinical trial, Fort Detrick, Strategic National Stockpile, United States, United States Department of Health and Human Services, US Food and Drug Administration, US government, VaxGen